Oligonucleotide Delivery System Market Size, Share & Trends Analysis Distribution by Delivery System (Conjugation-Based Delivery Systems (GALNAc Conjugation, Ligand Conjugation, Antibody Conjugation, Targeting Moiety Conjugation), Nanoparticle-Based Delivery Systems (Lipid Nanoparticles (LNPs), Peptide Nanoparticles), Viral Vector-Based Delivery Systems (Adeno-associated Virus (AAV) Vectors, AAV9, Lentiviral Vectors, Others), Exosome-Based Delivery Systems, Liposomes, Others), Disease Indication and Segment Forecasts, 2024-2031

Report Id: 2779 Pages: 165 Last Updated: 20 September 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

The Oligonucleotide Delivery System Market is predicted to grow at an 12.4% CAGR during the forecast period for 2024-2031.

oligonucleotide

The delivery system of an oligonucleotide refers to the method and technologies applied for transferring oligonucleotides into cells where they could exert their therapeutic effects. Oligonucleotides, due to their size and chemical properties, face the challenge of penetration through the biological barriers to enter target cells. Efficacy and safety are therefore directly connected to effective delivery, making it critical for the effectiveness of oligonucleotide therapies. It has different types of therapeutic agents, which are named as follows: Antisense Oligonucleotides (ASOs), Small Interfering RNAs (siRNAs), Aptamers, MicroRNAs (miRNAs).

One of the most significant drivers is increased investment in gene therapy. Gene therapies are gaining popularity, and funding along with research into effective delivery mechanisms of oligonucleotides is increasing. Yet another driver for the market is an increase in regulatory approvals. Regulatory approval not only validates the efficacy of the gene therapy but also incites investment in the gene therapy.

Competitive Landscape

Some of the Key Players in Oligonucleotide Delivery System Market:

  • Biogen
  • Sarepta Therapeutics, Inc.
  • Jazz Pharmaceuticals plc
  • Ionis Pharmaceuticals, Inc.
  • Nippon Shinyaku Co., Ltd.
  • AstraZeneca
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG
  • Dicerna Pharmaceuticals, Inc. (Novo Nordisk)
  • IVERIC bio, Inc. (Astellas Pharma Inc.)
  • Elsie Biotechnologies (GSK)

Market Segmentation:

The oligonucleotide delivery system market is segmented by delivery system, disease indication. By delivery system market is segmented into conjugation-based delivery systems, nanoparticle-based delivery systems, exosome-based delivery systems, exosome-based delivery systems, liposomes, others. By conjugation-based delivery systems the market is sub segmented into GALNAc conjugation, ligand conjugation, antibody conjugation, targeting moiety conjugation. By nanoparticle-based delivery systems the market is sub segmented into lipid nanoparticles (LNPs), peptide nanoparticles. By viral vector-based delivery systems the market is sub segmented into adeno-associated virus (AAV) vectors, AAV9, lentiviral vectors, and others. By disease indication market is segmented into genetic disorders, infectious diseases, oncology, neurological disorders, others (autoimmune diseases, metabolic disorders, etc.)

Nanoparticle-based Delivery Systems is Expected to Drive the Oligonucleotide Delivery System Market

The growth of the oligonucleotide delivery market is attributed to nanoparticle-based delivery systems, including lipid nanoparticles and polymeric nanoparticles, due to their inherent ability to stabilize better cellular uptake and offering flexibility in the design. This makes it possible for oligonucleotides not to get degraded by nucleases until it reaches a target cell through the bloodstream. Also, LNPs are part of approved siRNA therapies called ONPATTRO and GIVLAARI. Nanoparticles can facilitate uptake by the cells via endocytosis and can be engineered with targeting ligands to increase their accuracy in delivery, thus minimizing off-target effects and enhancing efficacy in therapy. Their adaptive design allows changes in size, charge, and surface properties as well, which makes them better suited for a variety of therapeutic applications-from cancer, genetic disorders, to viral infections.

The Oncology Segment is Growing at the Highest Rate in the Oligonucleotide Delivery System Market.

Factors such as growing incidences of cancer, promising clinical outcomes, and rapid development in delivery technologies are the main drivers of such growth for the oncology segment. The leading cause of death worldwide, diagnosed cancer cases pose heavy demand for such innovative treatments as ASOs and siRNAs that can target genes which may be core to the progression of cancer. While no oligonucleotide drugs for cancer have been approved so far, several clinical trials in progress have given encouraging results and 229 trials were registered until early 2021.

Regionally, North America Led the Oligonucleotide Delivery System Market.

North America is expected to dominate the oligonucleotide delivery system market primarily due to its robust R&D infrastructure, high investment in life sciences, support by regulators, and a higher incidence of genetic disorders. This region, particularly the U.S., is considered to have a robust R&D environment supporting leading biotechnology companies and organizations that research innovative oligonucleotide treatments. Investment in life sciences drives the development of personalized therapeutics, such as oligonucleotide therapies. The U.S. FDA has been supportive of these therapies, and it has streamlined the approval process and encouraged further research.

Oligonucleotide Delivery System Market Report Scope

Report Attribute Specifications
Market Size Value In 2022 USD XX.XX Bn
 Revenue Forecast In 2031 USD XX.XX Bn
Growth Rate CAGR CAGR of 12.4% from 2024 to 2031
Quantitative Units Representation of revenue in US$ Bn and CAGR from 2024 to 2031
Historic Year 2019 to 2023
Forecast Year 2024-2031
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Delivery System, Disease Indication and By Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia
Competitive Landscape Biogen, Sarepta Therapeutics, Inc., Jazz Pharmaceuticals plc, Ionis Pharmaceuticals, Inc., Nippon Shinyaku Co., Ltd., AstraZeneca, Alnylam Pharmaceuticals, Inc., Novartis AG, Dicerna Pharmaceuticals, Inc. (Novo Nordisk), IVERIC bio, Inc. (Astellas Pharma Inc.), Elsie Biotechnologies (GSK)
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape.                     
Pricing and Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of Oligonucleotide Delivery System Market

Oligonucleotide Delivery System Market by Delivery System

  • Conjugation-Based Delivery Systems
    • GALNAc Conjugation
    • Ligand Conjugation
    • Antibody Conjugation
    • Targeting Moiety Conjugation
  • Nanoparticle-Based Delivery Systems
    • Lipid Nanoparticles (LNPs)
    • Peptide Nanoparticles
  • Viral Vector-Based Delivery Systems
    • Adeno-associated Virus (AAV) Vectors
    • AAV9
    • Lentiviral Vectors
    • Others
  • Exosome-Based Delivery Systems
  • Liposomes
  • Others

oligonucleotide

Oligonucleotide Delivery System Market by Disease Indication

  • Genetic Disorders
  • Infectious Diseases
  • Oncology
  • Neurological Disorders
  • Others (Autoimmune Diseases, Metabolic Disorders, etc.)

Oligonucleotide Delivery System Market by Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Enter Details and Get your PDF Brochure

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
3424
Security Code field cannot be blank!

Frequently Asked Questions

The Oligonucleotide Delivery System Market is predicted to grow at an 12.4% CAGR during the forecast period for 2024-2031.

Biogen, Sarepta Therapeutics, Inc., Jazz Pharmaceuticals plc, Ionis Pharmaceuticals, Inc., Nippon Shinyaku Co., Ltd., AstraZeneca, Alnylam Pharmaceuti
Send Me the Sample Report Enquiry Before Buying